Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Oxford Ledge is still expanding full research coverage of TELO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Telomir Pharmaceuticals develops an oral small molecule, Telomir-1, targeting aging and age-related diseases through preclinical research prior to planned human trials.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-15
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-06-08
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-05-20
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Other material event 2026-04-30
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for TELO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open TELO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.